ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells

The ubiquitin-proteasome system has recently emerged as a major target for drug development in cancer therapy. The proteasome inhibitor bortezomib has clinical activity in multiple myeloma and mantle cell lymphoma. Here we report that Eeyarestatin I (EerI), a chemical inhibitor that blocks endoplasm...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wang, Qiuyan, Mora-Jensen, Helena, Weniger, Marc A., Perez-Galan, Patricia, Wolford, Chris, Hai, Tsonwin, Ron, David, Chen, Weiping, Trenkle, William, Wiestner, Adrian, Ye, Yihong
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: National Academy of Sciences 2009
Gaiak:
Biological Sciences
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2629785/
https://ncbi.nlm.nih.gov/pubmed/19164757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0807611106
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak